WCLC2016肺癌—奥希替尼AURA3研究结果公布 图文.ppt

Presented by VA Papadimitrakopoulou at the World Conference on Lung Cancer 2016 Plenary Session: PL03 Presidential Symposium (abstract PL03.03) Vassiliki A Papadimitrakopoulou1, Yi-Long Wu2, Myung-Ju Ahn3, Suresh S Ramalingam4, Marina Chiara Garassino5, Hye Ryun Kim6, Frances A Shepherd7, Hiroaki Akamatsu8, Willemijn SME Theelen9, Chee Khoon Lee10, Martin Sebastian11, Alison Templeton12, Marcelo Marotti12, Serban Ghiorghiu12, Tony Mok13 Randomised Phase III study of osimertinib vs platinum-pemetrexed for EGFR T790M-positive advanced NSCLC (AURA3) 1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Guangdong Lung Cancer Institute, Guangdong General Hospital Guangdong Academy of Medical Sciences, Guangzhou, China; 3Samsung Medical Center, Seoul, Republic of Korea; 4Emory University, Winship Cancer Institute, Atlanta, GA, USA; 5Medical Oncology Department, Thoracic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 6Department of Internal Medicine, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea; 7Princess Margaret Cancer Centre, Toronto, Canada; 8Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan; 9Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 10St George Hospital, Clinical Research Unit, Division of Cancer Services, Pitney Clinical Sciences Building, Kogarah, New South Wales, Australia; 11University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; 12AstraZeneca, Cambridge, UK; 13Key Laboratory of South China, Department of Clinical Oncology, The Chinese University of Hong Kong, Sha Tin, Hong Kong Disclosures Vassiliki A Papadimitrakopoulou: consultancy for AstraZeneca, ARIAD, BMS, Genentech, Biothera, Janssen, Clovis, Merck, Eli Lilly; grants / research support from AstraZeneca, Genentech, Merck, BMS, Novartis, Janssen, AC